The pace of science is accelerating, but it can still take years to deploy lab and manufacturing space. This requires large upfront capital expenditures, long-term financial commitments, and often results in rigid facilities that are designed for a single purpose. SmartLabs enables life sciences companies to outsource their infrastructure and accelerate their timelines. Its new CleanSuites provides a solution to clinical manufacturing that delivers rapid access to FDA-compliant cGMP manufacturing space where companies can develop and own their own processes and move faster from the lab to the clinic. We spoke to Brian Taylor, executive vice president of biopharma solutions for SmartLabs, about the infrastructure challenges life sciences companies face today, SmartLabs CleanSuites, and how they bring speed and flexibility to therapeutic developers.
